☆ 4.6 Editorial Material

Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud

EUROPEAN RESPIRATORY JOURNAL (2023)

Related references

Note: Only part of the references are listed.

Review Critical Care Medicine

Progress in the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Steven D. Nathan

Summary: Pulmonary hypertension, a common complication of fibrotic interstitial lung disease, is associated with increased morbidity and mortality. The effectiveness of treatment for pulmonary hypertension in the context of interstitial lung disease has been uncertain, with some studies suggesting benefit and others demonstrating harm. However, recent research has shown the potential benefits of treatment, leading to the approval of the first therapy for patients with interstitial lung disease complicated by pulmonary hypertension in the United States. This review also provides a management algorithm and considerations for future clinical trials.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Add to Collection

Article Critical Care Medicine

Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes

Steven D. Nathan et al.

Summary: Higher dosages of inhaled treprostinil have been shown to have greater benefits in preventing clinical worsening and achieving clinical improvement in patients with pulmonary hypertension resulting from interstitial lung disease.

CHEST (2023)

Add to Collection

Article Respiratory System

Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study

Aaron Waxman et al.

Summary: This study evaluated the long-term effects of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. The results support the long-term safety and efficacy of inhaled treprostinil in these patients.

EUROPEAN RESPIRATORY JOURNAL (2023)

Add to Collection

Article Respiratory System

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Marc Humbert et al.

EUROPEAN RESPIRATORY JOURNAL (2023)

Add to Collection

Article Critical Care Medicine

Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial

Steven D. Nathan et al.

Summary: The study showed that patients treated with inhaled treprostinil had better outcomes in terms of 6-minute walk distance and fewer clinical worsening events. There were fewer occurrences of multiple disease progression events in the inhaled treprostinil group, indicating a lower risk of further disease progression in these patients.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Add to Collection

Article Critical Care Medicine

Syndrome of Combined Pulmonary Fibrosis and Emphysema An Official ATS/ERS/JRS/ALAT Research Statement

Vincent Cottin et al.

Summary: This research summarizes the definition, characteristics, pathophysiology, and research priorities of combined pulmonary fibrosis and emphysema (CPFE). The research proposes CPFE to be recognized as a syndrome and offers classification criteria and descriptions of radiologic and pathological patterns.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension

Sylvia M. Nikkho et al.

Summary: Pulmonary hypertension is strongly associated with worse outcomes in chronic lung diseases, especially when underlying interstitial lung disease is present. Researching this issue is essential for future studies and improving the care and quality of life for affected patients.

PULMONARY CIRCULATION (2022)

Add to Collection

Article Respiratory System

A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen

Christopher S. King et al.

Summary: Treatment with INOpulse improves physical activity and symptoms in patients with interstitial lung disease requiring supplemental oxygen, with good tolerability.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2022)

Add to Collection

Article Critical Care Medicine

Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial

Juergen Behr et al.

Summary: The study aimed to assess the efficacy and safety of sildenafil added to pirfenidone versus placebo in patients with advanced IPF at risk of pulmonary hypertension. The results showed that sildenafil did not provide a treatment benefit compared to placebo up to 52 weeks, with no new safety signals identified. Further research is needed to determine if specific subgroups of IPF patients might benefit from sildenafil.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

Aaron Waxman et al.

Summary: In patients with pulmonary hypertension due to interstitial lung disease, inhaled treprostinil significantly improved exercise capacity and clinical outcomes compared to placebo in a 16-week trial. Adverse events such as cough, headache, dyspnea, dizziness, nausea, fatigue, and diarrhea were commonly reported.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study

Steven D. Nathan et al.

Summary: The study analyzed patients with pulmonary hypertension associated with idiopathic interstitial pneumonia using high-resolution computed tomography scans. It found that patients with combined pulmonary fibrosis and emphysema (CPFE) had higher mortality rates, with those having more emphysema than fibrosis facing increased risk of poor outcomes.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2021)

Add to Collection

Article Critical Care Medicine

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study

Steven D. Nathan et al.

Summary: The INCREASE trial demonstrated that inhaled treprostinil improved FVC in patients with ILD and associated pulmonary hypertension, with more significant effects observed in specific subgroups, suggesting its potential as a therapeutic option for pulmonary fibrosis.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis

Steven D. Nathan et al.

CHEST (2020)

Add to Collection

Article Critical Care Medicine

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study

Steven D. Nathan et al.

LANCET RESPIRATORY MEDICINE (2019)

Add to Collection

Article Respiratory System

Pulmonary hypertension in chronic lung disease and hypoxia

Steven D. Nathan et al.

EUROPEAN RESPIRATORY JOURNAL (2019)

Add to Collection

Editorial Material Respiratory System

The unmet medical need of pulmonary hypertension in idiopathic pulmonary fibrosis

Vincent Cottin et al.

EUROPEAN RESPIRATORY JOURNAL (2018)

Add to Collection

Article Medicine, General & Internal

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis

Martin Kolb et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Critical Care Medicine

Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia

Tamera J. Corte et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)

Add to Collection

Article Medicine, General & Internal

Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan A Parallel, Randomized Trial

Ganesh Raghu et al.

ANNALS OF INTERNAL MEDICINE (2013)

Add to Collection

Editorial Material Respiratory System

Treatment of pulmonary hypertension in interstitial lung disease: do not throw out the baby with the bath water

Vincent Cottin

EUROPEAN RESPIRATORY JOURNAL (2013)

Add to Collection

Article Respiratory System

Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial

Ganesh Raghu et al.

EUROPEAN RESPIRATORY JOURNAL (2013)

Add to Collection

Article Respiratory System

Pulmonary Hypertension as a Prognostic Indicator at the Initial Evaluation in Idiopathic Pulmonary Fibrosis

Motohiro Kimura et al.

RESPIRATION (2013)

Add to Collection

Article Critical Care Medicine

BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis

Talmadge E. King et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)

Add to Collection

Article Respiratory System

Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome

V. Cottin et al.

EUROPEAN RESPIRATORY JOURNAL (2010)

Add to Collection

Article Respiratory System

Sildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis

Robert M. Jackson et al.

LUNG (2010)

Add to Collection

Article Medicine, General & Internal

A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis

David A. Zisman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Biochemistry & Molecular Biology

Prostaglandin E2 induces fibroblast apoptosis by modulating multiple survival pathways

Steven K. Huang et al.

FASEB JOURNAL (2009)

Add to Collection

Article Respiratory System

Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis

Steven D. Nathan et al.

RESPIRATION (2008)

Add to Collection

Article Cardiac & Cardiovascular Systems

Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis

Steven D. Nathan et al.

RESPIRATORY MEDICINE (2008)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis

David A. Zisman et al.

RESPIRATORY MEDICINE (2007)

Add to Collection

Article Respiratory System

Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant

A. F. Shorr et al.

EUROPEAN RESPIRATORY JOURNAL (2007)

Add to Collection

Article Critical Care Medicine

Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis

CJ Lettieri et al.

CHEST (2006)

Add to Collection

Article Biochemistry & Molecular Biology

Prostaglandin E-2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation

JE Kolodsick et al.

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.